People: Agenus Inc (AGEN.PH)

AGEN.PH on Philadelphia Stock Exchange

3.02USD
3:36pm EDT
Price Change (% chg)

$0.04 (+1.34%)
Prev Close
$2.98
Open
$2.98
Day's High
$3.02
Day's Low
$2.90
Volume
1,100
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Stein, Robert 

Brief Biography

Dr. Robert B. Stein, M.D., Ph.D., is a Chief Scientific Officer of Agenus Inc. Dr. Stein leads our Research, Preclinical Development and Translational Medicine functions and helps shape our clinical development strategy for the Prophage Series vaccines and HerpV. In addition, he is leading the integration of 4-Antibody into our business. Dr. Stein brings over 30 years of experience and accomplishments in the pharmaceutical and biotech industry to the Agenus leadership team. Over the course of his career Dr. Stein has played a pivotal role in bringing eight drugs to the market including Sustiva, Fablyn, Viviant, PanRetin, TargRetin, Promacta, & Eliquis. Prior to joining Agenus he held a number of senior management positions including Chief Scientific Officer & Senior Vice President of Research for Ligand Pharmaceuticals, Executive Vice President of Research & Preclinical Development for Dupont Merck, President and Chief Scientific Officer for Incyte Pharmaceuticals, President of Roche Palo Alto and CEO of KineMed. Dr. Stein spent the early part of his career at Merck, Sharp and Dohme Research Laboratories. He holds an MD and a PhD in Physiology & Pharmacology from Duke University. Dr. Stein filed a personal voluntary bankruptcy petition under Chapter 7 in August of 2012 and the bankruptcy was discharged in May 2013.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Garo Armen

1,589,170

Christine Klaskin

437,697

Robert Stein

--

Karen Valentine

551,954

Ozer Baysal

587,802

Timothy Wright

--
As Of 30 Dec 2013
Search Stocks